Order Details:
Complete Case 3-2: Amgen Whistle blowing Read the above case and write up an executive summary on the case, including answers to the following questions.
1. How did Amgen’s unethical behavior contribute to the problems with Medicaid kickbacks?
2. Why does the public consider this scandal to have an unethical dilemma?
3. Explain what is meant by whistle blowing?Include your opinions and identify any gaps between public expectations of ethical standards and universal professional codes of ethical standards.
Case 3-2 Amgen Whistle blowing Case Amgen, a Thousand Oaks, California–based company, had the unenviable task of dealing with lawsuits filed by 15 states in 2009 alleging a Medicaid kickback scheme.1 To make matters worse, two additional whistle blowing lawsuits were filed against the company in Ventura County. The complaints, which don’t appear related to the fraud alleged by the group of states, were brought by former employees who said they had uncovered wrongdoing at the biotech giant and were terminated after they raised red flags to superiors. One employee alleged the company violated federal law by under-reporting complaints and problems with the company’s drugs after they hit the market. The facts of that lawsuit are described below.
Former Amgen employee Shawn O’Brien sued Amgen for wrongful termination on October 9, 2009, alleging he was laid off in October 2007 in retaliation for raising concerns about how the company reported complaints and problems with drugs already on the market. O’Brien worked as a senior project manager for Amgen’s “Ongoing Change Program,” according to the lawsuit filed in Ventura County Superior Court. His job was to improve Amgen’s “compliance processes with high inherent risk to public safety, major criminal and civil liability, or both,” according to the lawsuit.The lawsuit alleged that in April 2007, Amgen’s board of directors flagged the company’s process for dealing with post-market complaints about drugs as a potential problem. Federal law requires drug companies to track and report to the Food and Drug Administration any problems with their drugs after they hit the market. In June 2007, O’Brien was put on the case. He soon uncovered facts that Amgen was not adequately and consistently identifying phone calls or mail related to post-marketing adverse events of product complaints. That year, O’Brien warned the company about the seriousness of the issues but, he claims, the company would not take any action or offer any support. In August 2007, O’Brien took his complaint to a senior executive/corporate officer (unnamed) and warned that Amgen’s process for dealing with post-market problems wasn’t adequate.
Pre-Written Pages:4
*Please note down the Number of Pages & Order Topic before place the Pre-Written Order
*Please note that pre-written orders are previously submitted orders by students and tutors. They are not plagiarism-free and should only be used for reference or better understanding of the topic.
If you require newly written order then please select custom order. We guarantee that the completed custom order will be free of plagiarism.
